Tumor sequencing for therapeutic targeting
Total Trials
6
As Lead Sponsor
4
As Collaborator
2
Total Enrollment
58,693
NCT02735252
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
Phase: N/A
Role: Collaborator
Start: May 25, 2016
Completion: Mar 31, 2027
NCT03061305
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Role: Lead Sponsor
Start: Nov 30, 2016
Completion: Jun 27, 2024
NCT04087018
Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors
Phase: Phase 1
Start: Sep 24, 2019
Completion: Jun 17, 2024
NCT05082701
Sentinel™ Trial: A Prospective Study Evaluating the Performance and Clinical Benefit of Personalized ctDNA-based MRD Testing to Detect Recurrence and Monitor Treatment Response in Patients With Solid Tumors
Start: Dec 3, 2021
Completion: Feb 22, 2024
NCT05097599
StrataPATH™ (Precision Indications for Approved Therapies)
Phase: Phase 2
Start: Apr 29, 2022
Completion: Jun 12, 2024
NCT05312307
Strata EXPress™: A Study Using StrataEXP™ to Identify RNA-Expression Biomarkers in Advanced Cancer Patients
Start: Feb 6, 2023
Loading map...